Dutch biotech garners €15M in venture round
San Francisco-based Alta Partners took the lead role in a €15 million round of venture financing for Kiadis Pharma, an oncology drug developer. The Amsterdam-based company is developing therapies for bone marrow transplants and the treatment of aggressive cancers. Its four most advanced products are currently in clinical trials, ranging from Phase I to entering Phase III. Kiadis Pharma's lead product is ATIR, which enables the use of mis-matched bone-marrow donors in transplantations for terminally ill blood cancer patients.
- check out the release on the round
Related Article:
Kiadis to merge with Canada's Celmed. Report
Be the first to comment
More stories about Phase III pharmaceuticals drug developer Venture Capital cancer drug Cancer blood cancer
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
